Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
RCUS

RCUS - Arcus Biosciences Inc Stock Price, Fair Value and News

$21.95-0.75 (-3.30%)
Market Closed

45/100

RCUS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

45/100

RCUS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

RCUS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RCUS Price Action

Last 7 days

-0.7%

Last 30 days

2.8%

Last 90 days

2.0%

Trailing 12 Months

130.1%

RCUS RSI Chart

RCUS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RCUS Valuation

Market Cap

2.8B

Price/Earnings (Trailing)

-7.79

Price/Sales (Trailing)

11.14

EV/EBITDA

-7.82

Price/Free Cashflow

-5.68

RCUS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

RCUS Fundamentals

RCUS Revenue

Revenue (TTM)

247.0M

Rev. Growth (Yr)

26.92%

Rev. Growth (Qtr)

26.92%

RCUS Earnings

Earnings (TTM)

-353.0M

Earnings Growth (Yr)

-12.77%

Earnings Growth (Qtr)

21.48%

RCUS Profitability

EBT Margin

-142.91%

Return on Equity

-55.94%

Return on Assets

-30.99%

Free Cashflow Yield

-17.59%

RCUS Investor Care

Shares Dilution (1Y)

18.43%

Diluted EPS (TTM)

-3.3

RCUS Alerts

  • Big jump in Revenue (Y/Y)
  • Losses in recent quarter

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025141.0M262.0M240.0M247.0M
2024237.0M247.0M263.0M258.0M
2023119.0M121.0M120.0M117.0M
2022391.5M409.1M432.6M112.0M
202185.7M93.4M38.4M383.0M
202015.0M15.0M77.8M78.0M
20198.9M9.4M6.8M15.0M
20182.7M3.9M8.0M8.4M
20170001.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About Arcus Biosciences Inc

RCUS
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT investigational monoclonal antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
 CEO
 WEBSITEarcusbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES500

Arcus Biosciences Inc Frequently Asked Questions

RCUS is the stock ticker symbol of Arcus Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Arcus Biosciences Inc is 2.75 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, RCUS's PE ratio (Price to Earnings) is -7.79 and Price to Sales (PS) ratio is 11.14. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RCUS PE ratio will change depending on the future growth rate expectations of investors.